Merck inks $22B cancer drug deal with Daiichi Sankyo


Merck Fails To Collect Revenue Claimed

Erik S. Lesser/Getty Images News

Merck (NYSE:MRK) announced Thursday an agreement with Japanese pharma Daiichi Sankyo (OTCPK:DSKYF) to jointly develop and commercialize three antibody-drug conjugates (ADC) targeted at solid tumors.

The deal covers ADCs, patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). They are currently undergoing studies as monotherapy and

Source link

Leave A Reply

Your email address will not be published.